Dyax (NASDAQ: [[ticker:DYAX]]), the Cambridge, MA-based maker of a drug for a rare inflammatory disease, said today it has raised $51.8 million in a stock offering. The company sold 17 million shares at $3.25 apiece in a deal underwritten by Jefferies & Company and Needham & Company. Dyax plans to use the money on the commercial push for ecallantide (Kalbitor), a drug for acute attacks of hereditary angioedema.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
